Modified risk stratification (MRS) for Multiple Myeloma- A simplified model using machine learning

Abstract

Risk stratification provides an important clue that helps clinicians decide differential medical treatment. The staging system for multiple myeloma (MM) has evolved with advancement of treatment protocols, from Salmon Durie staging to International Staging System (ISS) to Revised-ISS (R-ISS). The R-ISS is based on serum levels of albumin (alb), β₂ microglobulin (β₂m), lactate dehydrogenase (LDH) and cytogenetic aberrations using fluorescent in-situ hybridization (FISH). Because of limited availability of FISH-based testing, R-ISS for MM has not been applied widely in most developing countries. In this study, we attempt to devise a staging system based on simple laboratory parameters in MM patients treated with novel agents.